Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.

MLA

Line S Tarpgaard, et al. “Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study.” PLoS ONE, vol. 9, no. 2, Jan. 2014, p. e87746. EBSCOhost, https://doi.org/10.1371/journal.pone.0087746.

APA

Line S Tarpgaard, Tormod K Guren, Bengt Glimelius, Ib J Christensen, Per Pfeiffer, Elin H Kure, Halfdan Sorbye, Tone Ikdahl, Mette Yilmaz, Julia S Johansen, & Kjell Magne Tveit. (2014). Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study. PLoS ONE, 9(2), e87746. https://doi.org/10.1371/journal.pone.0087746

Chicago

Line S Tarpgaard, Tormod K Guren, Bengt Glimelius, Ib J Christensen, Per Pfeiffer, Elin H Kure, Halfdan Sorbye, et al. 2014. “Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study.” PLoS ONE 9 (2): e87746. doi:10.1371/journal.pone.0087746.